Crizotinib in Advanced Lung Adenocarcinoma Patients with ALK or ROS-1 Rearrangement: Is it the Same?

被引：0
|
作者：
Han, B. [1 ]
Zhang, B. [1 ]
Xu, J. [1 ]
Zhang, Y. [1 ]
Zhang, X. [1 ]
Chu, T. [1 ]
Wang, S. [1 ]
Qiao, R. [1 ]
Qian, J. [1 ]
Lu, J. [1 ]
Zhang, L. [1 ]
机构：
[1] Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
ALK; ros1; crizotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-29
引用
收藏
页码：S471 / S471
页数：1
相关论文
共 50 条
  • [21] Prevalence of ALK and ROS1 Rearrangements in Mexican Patients with Lung Adenocarcinoma
    Sanchez, Sergio
    Montilla, Silvia
    Matias, Pamela R.
    Garcia, Julieta
    Gonzalez, Ivan R.
    LABORATORY INVESTIGATION, 2016, 96 : 482A - 482A
  • [22] ROS-1 Rearranged Non-Small Cell Lung Cancer and Crizotinib: An Indian Experience
    Talreja, V.
    Patil, V.
    Joshi, A.
    Noronha, V.
    Mv, C.
    Kaushal, R.
    Mahajan, A.
    Janu, A.
    Prabhash, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2278 - S2278
  • [23] Analysis of our experience of ROS-1 patients in advanced NSCLC
    Pande, N.
    Joshi, A.
    Noronha, V.
    Patil, V.
    Mahajan, A.
    Prabhash, K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S99 - S99
  • [24] ROS-1, Robotic Surgery and renal Lesions in a Patient with metastatic Adenocarcinoma of the Lung
    Rehman, Attiq
    Wass, Romana
    Jordan, Franziska
    Rudelstorfer, Gregor
    Porsch, Peter
    Hutter, Joerg
    Mitterberger, Michael
    Hutarew, Gregor
    Sotlar, Karl
    Studnicka, Michael
    WIENER KLINISCHE WOCHENSCHRIFT, 2018, 130 (19-20) : 598 - 598
  • [25] Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease?
    Antoniu, Sabina Antonela
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2011, 15 (03) : 351 - 353
  • [26] ROS-1 TKI for the treatment of concurrent sarcomatoid transformation and acquired ROS-1 F2004C mutation in a lung adenocarcinoma patient
    Ko, H. -J.
    Hsu, C. -K.
    Yeh, Y. -C.
    Huang, H. -C.
    PULMONOLOGY, 2022, 28 (01): : 76 - 79
  • [27] 1st Line and Beyond for ALK, ROS-1, BRAF, RET, FGFR Positive Lung
    Spigel, David R.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S85 - S85
  • [28] A Validation Study for the Use of ROS-1 Immunohistochemistry in Screening for ROS-1 Translocations in Lung Cancer
    Viola, Patrizia
    Maurya, Manisha
    Croud, James
    Gazdova, Jana
    Suleman, Nadia
    Lim, Eric
    Popat, Sanjay
    Rice, Alexandra
    Fernandez, Angeles Montero
    De Castro, David Gonzalez
    Nicholson, Andrew G.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S694 - S694
  • [29] Cost-effectiveness analysis comparing companion diagnostic tests for EGFR, ALK and ROS-1 versus next-generation sequence (NGS) in advanced adenocarcinoma lung cancer patients.
    Schluckebier, Luciene
    Caetano, Rosangela
    Aran, Veronica
    Ferreira, Carlos G. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients with ALK Rearrangement: A Retrospective Study and Literature Review
    Han, B.
    Zhang, B.
    Zhang, Y.
    Xu, J.
    Zhang, X.
    Chu, T.
    Wang, S.
    Qian, J.
    Qiao, R.
    Lu, J.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S471 - S471
12345